A detailed history of Axiom Investors LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Axiom Investors LLC holds 54,860 shares of SUPN stock, worth $1.86 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
54,860
Previous 54,235 1.15%
Holding current value
$1.86 Million
Previous $1.85 Million 20.66%
% of portfolio
0.01%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$25.99 - $33.85 $16,243 - $21,156
625 Added 1.15%
54,860 $1.47 Million
Q1 2024

May 13, 2024

BUY
$27.11 - $35.17 $156,695 - $203,282
5,780 Added 11.93%
54,235 $1.85 Million
Q4 2023

Feb 12, 2024

BUY
$22.72 - $29.68 $791,564 - $1.03 Million
34,840 Added 255.89%
48,455 $1.4 Million
Q3 2023

Nov 13, 2023

SELL
$27.57 - $32.91 $283,557 - $338,479
-10,285 Reduced 43.03%
13,615 $375,000
Q2 2023

Aug 10, 2023

SELL
$29.91 - $38.73 $50,697 - $65,647
-1,695 Reduced 6.62%
23,900 $718,000
Q1 2023

May 12, 2023

BUY
$34.93 - $42.03 $187,050 - $225,070
5,355 Added 26.46%
25,595 $927,000
Q4 2022

Feb 09, 2023

BUY
$31.09 - $37.88 $629,261 - $766,691
20,240 New
20,240 $721,000
Q3 2018

Nov 13, 2018

SELL
$42.7 - $56.55 $2.44 Million - $3.24 Million
-57,230 Closed
0 $0
Q2 2018

Aug 13, 2018

BUY
$44.1 - $59.85 $245,637 - $333,364
5,570 Added 10.78%
57,230 $3.43 Million
Q1 2018

May 14, 2018

SELL
$37.15 - $46.9 $186,864 - $235,907
-5,030 Reduced 8.87%
51,660 $2.37 Million
Q4 2017

Feb 14, 2018

SELL
$36.4 - $42.6 $1.54 Million - $1.8 Million
-42,186 Reduced 42.67%
56,690 $2.26 Million
Q3 2017

Nov 09, 2017

SELL
$36.75 - $49.65 $2.68 Million - $3.62 Million
-72,955 Reduced 42.46%
98,876 $3.96 Million
Q2 2017

Aug 14, 2017

BUY
N/A
171,831
171,831 $7.41 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.82B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Axiom Investors LLC Portfolio

Follow Axiom Investors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Axiom Investors LLC , based on Form 13F filings with the SEC.

News

Stay updated on Axiom Investors LLC with notifications on news.